Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Revance Therapeutics Inc (NASDAQ: RVNC) closed at $3.64 in the last session, down -3.70% from day before closing price of $3.78. In other words, the price has decreased by $-3.70 from its previous closing price. On the day, 1.81 million shares were traded. RVNC stock price reached its highest trading level at $3.87 during the session, while it also had its lowest trading level at $3.615.
Ratios:
We take a closer look at RVNC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.
On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.
Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 16 ’24 when Jordan Erica sold 2,392 shares for $3.80 per share. The transaction valued at 9,096 led to the insider holds 114,864 shares of the business.
Schilke Tobin sold 9,361 shares of RVNC for $47,204 on Mar 18 ’24. The CFO now owns 192,666 shares after completing the transaction at $5.04 per share. On Mar 18 ’24, another insider, Sjuts Dustin S, who serves as the President of the company, sold 9,211 shares for $5.04 each. As a result, the insider received 46,446 and left with 167,550 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 379346240 and an Enterprise Value of 545618176. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.62. Its current Enterprise Value per Revenue stands at 2.331 whereas that against EBITDA is -2.635.
Stock Price History:
The Beta on a monthly basis for RVNC is 1.16, which has changed by -0.88495576 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, RVNC has reached a high of $37.98, while it has fallen to a 52-week low of $3.62. The 50-Day Moving Average of the stock is -30.09%, while the 200-Day Moving Average is calculated to be -65.37%.
Shares Statistics:
According to the various share statistics, RVNC traded on average about 1.78M shares per day over the past 3-months and 1816430 shares per day over the past 10 days. A total of 104.22M shares are outstanding, with a floating share count of 95.22M. Insiders hold about 8.63% of the company’s shares, while institutions hold 75.49% stake in the company. Shares short for RVNC as of 1711584000 were 13551210 with a Short Ratio of 7.61, compared to 1709164800 on 11879422. Therefore, it implies a Short% of Shares Outstanding of 13551210 and a Short% of Float of 14.930001.
Earnings Estimates
The market rating for Revance Therapeutics Inc (RVNC) is a result of the insights provided by 4 analysts actively involved in the assessment.On average, analysts expect EPS of $-0.75 for the current quarter, with a high estimate of $-0.5 and a low estimate of $-1.19, while EPS last year was $-0.74. The consensus estimate for the next quarter is $-0.51, with high estimates of $-0.46 and low estimates of $-0.56.
Analysts are recommending an EPS of between $-1.61 and $-3.24 for the fiscal current year, implying an average EPS of $-2.3. EPS for the following year is $-1.06, with 5 analysts recommending between $-0.78 and $-1.22.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $56.63M. It ranges from a high estimate of $59.6M to a low estimate of $53.47M. As of the current estimate, Revance Therapeutics Inc’s year-ago sales were $49.33M, an estimated increase of 14.80% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $68.21M, an increase of 17.30% over than the figure of $14.80% in the same quarter last year. There is a high estimate of $72.83M for the next quarter, whereas the lowest estimate is $64M.
A total of 10 analysts have provided revenue estimates for RVNC’s current fiscal year. The highest revenue estimate was $288M, while the lowest revenue estimate was $272.88M, resulting in an average revenue estimate of $281.72M. In the same quarter a year ago, actual revenue was $234.04M, up 20.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $382.52M in the next fiscal year. The high estimate is $406.96M and the low estimate is $341M. The average revenue growth estimate for next year is up 35.80% from the average revenue estimate for this year.
